[go: up one dir, main page]

WO2007075859A3 - Systems and methods for the delivery of corticosteroids having an increased lung deposition - Google Patents

Systems and methods for the delivery of corticosteroids having an increased lung deposition Download PDF

Info

Publication number
WO2007075859A3
WO2007075859A3 PCT/US2006/048735 US2006048735W WO2007075859A3 WO 2007075859 A3 WO2007075859 A3 WO 2007075859A3 US 2006048735 W US2006048735 W US 2006048735W WO 2007075859 A3 WO2007075859 A3 WO 2007075859A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
systems
methods
corticosteroids
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048735
Other languages
French (fr)
Other versions
WO2007075859A2 (en
Inventor
Malcolm R Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tika Lakemedel AB
Original Assignee
Tika Lakemedel AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tika Lakemedel AB filed Critical Tika Lakemedel AB
Priority to EP06847888A priority Critical patent/EP1971348A2/en
Priority to JP2008547534A priority patent/JP2009520827A/en
Publication of WO2007075859A2 publication Critical patent/WO2007075859A2/en
Anticipated expiration legal-status Critical
Publication of WO2007075859A3 publication Critical patent/WO2007075859A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies.
PCT/US2006/048735 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids having an increased lung deposition Ceased WO2007075859A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06847888A EP1971348A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids having an increased lung deposition
JP2008547534A JP2009520827A (en) 2005-12-20 2006-12-19 System and method for delivering corticosteroids with increased lung deposition

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US75276505P 2005-12-20 2005-12-20
US75273505P 2005-12-20 2005-12-20
US75233205P 2005-12-20 2005-12-20
US60/752,332 2005-12-20
US60/752,735 2005-12-20
US60/752,765 2005-12-20
US77399906P 2006-02-15 2006-02-15
US77399806P 2006-02-15 2006-02-15
US60/773,998 2006-02-15
US60/773,999 2006-02-15
US82009206P 2006-07-21 2006-07-21
US82009606P 2006-07-21 2006-07-21
US82009406P 2006-07-21 2006-07-21
US60/820,094 2006-07-21
US60/820,096 2006-07-21
US60/820,092 2006-07-21

Publications (2)

Publication Number Publication Date
WO2007075859A2 WO2007075859A2 (en) 2007-07-05
WO2007075859A3 true WO2007075859A3 (en) 2008-12-11

Family

ID=38218568

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2006/048927 Ceased WO2007075963A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids
PCT/US2006/048631 Ceased WO2007075801A2 (en) 2005-12-20 2006-12-19 Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
PCT/US2006/048630 Ceased WO2007075800A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids
PCT/US2006/048629 Ceased WO2007075799A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
PCT/US2006/048735 Ceased WO2007075859A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids having an increased lung deposition
PCT/US2006/048628 Ceased WO2007075798A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an increased lung deposition

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/US2006/048927 Ceased WO2007075963A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids
PCT/US2006/048631 Ceased WO2007075801A2 (en) 2005-12-20 2006-12-19 Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
PCT/US2006/048630 Ceased WO2007075800A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids
PCT/US2006/048629 Ceased WO2007075799A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048628 Ceased WO2007075798A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an increased lung deposition

Country Status (5)

Country Link
EP (6) EP1971348A2 (en)
JP (6) JP2009520821A (en)
BR (1) BRPI0620225A2 (en)
CA (2) CA2634398A1 (en)
WO (6) WO2007075963A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US7973929B2 (en) * 2007-11-16 2011-07-05 Particle Measuring Systems, Inc. System and method for calibration verification of an optical particle counter
AR073796A1 (en) * 2008-10-10 2010-12-01 Schering Corp CORTICOSTEROID FORMULATIONS AND THEIR TREATMENT METHODS
CA2934961A1 (en) * 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation
BR112016022405A2 (en) * 2014-03-28 2017-08-15 Univ Liege COMPOSITIONS OF CYCLODEXTRIN AND BUDESONIDE DERIVATIVE AND METHODS
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
US11672781B2 (en) 2018-05-07 2023-06-13 Prana Biosciences Inc Metaxalone formulations
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
CN113491677B (en) * 2020-03-18 2023-09-26 南京知和医药科技有限公司 Novel medicinal antiviral drug inhalant preparation and preparation method thereof
WO2022217029A1 (en) * 2021-04-09 2022-10-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20020183293A1 (en) * 2001-04-17 2002-12-05 Banerjee Partha S. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2005065649A1 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2002060896A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
CA2441744C (en) * 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DK1585548T3 (en) * 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP1689390B1 (en) * 2003-11-21 2011-02-09 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20020183293A1 (en) * 2001-04-17 2002-12-05 Banerjee Partha S. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2005065649A1 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid

Also Published As

Publication number Publication date
WO2007075801A3 (en) 2008-12-31
EP1971346A2 (en) 2008-09-24
EP1971348A2 (en) 2008-09-24
WO2007075801A2 (en) 2007-07-05
JP2009520822A (en) 2009-05-28
BRPI0620225A2 (en) 2011-11-01
JP2009524590A (en) 2009-07-02
WO2007075798A2 (en) 2007-07-05
EP1973550A2 (en) 2008-10-01
WO2007075963A2 (en) 2007-07-05
WO2007075799A3 (en) 2009-01-15
WO2007075963A3 (en) 2008-11-27
WO2007075798A3 (en) 2008-11-20
EP1971349A2 (en) 2008-09-24
WO2007075798A9 (en) 2007-08-23
CA2634413A1 (en) 2007-07-05
JP2009520827A (en) 2009-05-28
EP1971347A2 (en) 2008-09-24
JP2009520821A (en) 2009-05-28
CA2634398A1 (en) 2007-07-05
JP2009520823A (en) 2009-05-28
WO2007075859A2 (en) 2007-07-05
WO2007075800A2 (en) 2007-07-05
WO2007075799A2 (en) 2007-07-05
JP2009520828A (en) 2009-05-28
WO2007075800A3 (en) 2008-11-20
EP1971345A2 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
WO2007075859A3 (en) Systems and methods for the delivery of corticosteroids having an increased lung deposition
WO2005074990A3 (en) Methods of preventing and treating sars using low ph respiratory tract compositions
WO2007095339A3 (en) Methods of manufacturing corticosteroid solutions
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
WO2008053221A3 (en) Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
TN2012000446A1 (en) Pyridine and pyrazine derivative for the treatment of cf
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2007042035A3 (en) Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2008025787A3 (en) Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2009134524A3 (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
PT1845994E (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
EP4245368A3 (en) Migraine prevention and treatment
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
WO2006117299A3 (en) Novel crystalline forms of tiotropium bromide
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2007133944A3 (en) Topical administration of acyclovir
WO2009019598A3 (en) Inhalation therapy for respiratory disorders
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
MX2007002525A (en) Diphenylethylene compounds and uses thereof.
WO2008081268A3 (en) Pharmaceutical compositions of entacapone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008547534

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006847888

Country of ref document: EP